Molecular Imaging Genetics of Methylphenidate Response in ADHD and Substance Use Comorbidity

Molecular Imaging Genetics of Methylphenidate Response in ADHD and Substance Use Comorbidity

Author Szobot, Claudia M. Google Scholar
Roman, Tatiana Google Scholar
Hutz, Mara H. Google Scholar
Genro, Julia P. Google Scholar
Shih, Ming Chi Autor UNIFESP Google Scholar
Hoexter, Marcelo Q. Autor UNIFESP Google Scholar
Junior, Neivo Google Scholar
Pechansky, Flavio Google Scholar
Bressan, Rodrigo A. Autor UNIFESP Google Scholar
Rohde, Luis A. P. Google Scholar
Institution Univ Fed Rio Grande do Sul
UFRGS
Univ Luterana Brasil
Universidade Federal de São Paulo (UNIFESP)
Irmandade Santa Casa Misericordia
Abstract Purpose: Attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) are highly comorbid and may share a genetic vulnerability. Methylphenidate (MPH), a dopamine transporter (DAT) blocker, is an effective drug for most ADHD patients. Although dopamine D4 receptor (DRD4) and dopamine transporter (DAT1) genes have a role in both disorders, little is known about how these genes influence brain response to MPH in individuals with ADHD/SUDs. the goal of this study was to evaluate whether ADHD risk alleles at DRD4 and DAT1 genes could predict the change in striatal DAT occupancy after treatment with MPH in adolescents with ADHD/SUDs. Methods: Seventeen adolescents with ADHD/SUDs underwent a SPECT scan with [Tc 99m] TRODAT-1 at baseline and after three weeks on MPH. Caudate and putamen DAT binding potential was calculated. Comparisons on DAT changes were made according to the subjects' genotype. Results: the combination of both DRD4 7-repeat allele (7R) and homozygosity for the DAT1 10-repeat allele (10/10) was significantly associated with a reduced DAT change after MPH treatment in right and left caudate and putamen, even adjusting the results for potential confounders (P <= 0.02; R(2) from 0.50 to 0.56). Conclusions: in patients with ADHD/SUDs, combined DRD4 7R and DAT1 10/10 could index MPH reduced DAT occupancy. This might be important for clinical trials, in terms of better understanding individual variability in treatment response. Synapse 65: 154-159, 2011. (c) 2010 Wiley-Liss, Inc.
Keywords attention-deficit/hyperactivity disorder
substance use disorders
methylphenidate
SPECT
DRD4
DAT1
Language English
Date 2011-02-01
Published in Synapse. Hoboken: Wiley-liss, v. 65, n. 2, p. 154-159, 2011.
ISSN 0887-4476 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 154-159
Origin http://dx.doi.org/10.1002/syn.20829
Access rights Closed access
Type Article
Web of Science ID WOS:000285791900009
URI http://repositorio.unifesp.br/handle/11600/33400

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account